HLA
PMVP icon

Hamilton Lane Advisors’s PMV Pharmaceuticals PMVP Stock Holding History

Hamilton Lane Advisors’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,154
Closed -$202K – 86
2021
Q1 		$202K Buy
+6,154
New +$243K 0.07% 64

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Hamilton Lane Advisors's PMVP Position: Q2 2021 in Review

Hamilton Lane Advisors sold out of PMV Pharmaceuticals (PMVP) in Q2 2021, closing a stake of 6,154 shares — an estimated $202K sold.

Hamilton Lane Advisors first reported a position in PMVP in Q1 2021 and held it in 1 quarter. The position peaked at $202K in Q1 2021. 85 funds tracked by Wall St. Rank hold PMVP as of Q2 2021.

  • Hamilton Lane Advisors reported no remaining PMV Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Hamilton Lane Advisors sold 6,154 PMV Pharmaceuticals shares in Q2 2021, an estimated $202K.
  • Hamilton Lane Advisors first reported a position in PMV Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Hamilton Lane Advisors's PMV Pharmaceuticals position peaked at $202K in Q1 2021.
  • 85 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2021.

Based on Hamilton Lane Advisors's 13F filing for Q2 2021, filed 20 Jul 2021.